System and methods for optimized drug delivery and progression of diseased and normal cells

• US 6,871,171 B1
• Filed: 10/19/2000
• Issued: 03/22/2005
• Est. Priority Date: 10/19/2000
• Status: Expired due to Term

• Current Assignee: Optimata Ltd.
• Original Assignee: Optimata Ltd.
• Inventors: Vardi, Moshe, Skomorovski, Kirill, Agur, Zvia, Fleishmann, Sarel
• Primary Examiner(s): MORAN, MARJORIE A
• Application Number:
  US09/691,053
• Time in Patent Office: 1,615 Days
• Field of Search: 703/11, 703/2, 702/19, 705/3, 364/578
• US Class Current: 703/11
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: G16H 20/10 relating to drugs or medications, e.g. for ensuring correct administration to patients
• CPC Class Codes: G16H 50/50 for simulation or modelling of medical disorders

Abstract

Systems for recommending an optimal treatment protocol for a specific individual are disclosed. The systems comprise generally a system model, a plurality of treatment protocols, a system model modifier, wherein said system model is modified by the system model modifier based on parameters specific to the individual; and a selector to select an optimal treatment protocol from said plurality of treatment protocols based on the modified system model. Systems embodying the above techniques but for a general patient are also disclosed. Systems for a general patient and an individual for various specific diseases are disclosed. Methods and computer program products embodying the above techniques are also disclosed.

Claims

1. A computer system for recommending an optimal treatment protocol for treating cancer using drugs, for an individual, said system interfacing with the computer and said system further comprising:

a cancer system model;

a treatment protocol generator for generating a plurality of treatment protocols for treating cancer using drugs;

a system model modifier, wherein said system model modifier is adapted to modify said cancer system model based on parameters specific to the individual; and

a selector adapted to select an optimal treatment protocol from said plurality of treatment protocols based on the modified system model.

2. The system of claim 1 wherein the system model further comprises:

a process model of cancer development; and

a treatment model that is adapted to model the effects of treating cancer with drugs.

3. The system of claim 2 wherein said process model incorporates a distribution of cycling cells and quiescent cells.

4. The system of claim 2 where a tumor cell cycle is divided into at least four compartments G1, S, G2 and M and a quiescent stage is denoted by G0, wherein each of said four compartments is further subdivided into sub-compartments and an ith sub-compartment representing cells of age i in the corresponding compartment, wherein the system is adapted to ensure that cells entering a compartment always enter a first sub-compartment of the compartment.

5. The system of claim 4 wherein the model is adapted to trace development of cancer cells using a predetermined set of parameters by calculating a number of cells in each sub-compartment using stepwise equations.

6. The system of claim 5 wherein the system is adapted to use a probability vector to determine a fraction of cells that leaves any sub-compartment in a compartment to move to a first sub-compartment of the next compartment.

7. The system of claim 5 where the system includes a set of control functions that are adapted to uniquely determine an outcome of every single step, wherein said control functions comprise age of cells, state of a current population and associated environment.

8. The system of claim 5 wherein the system comprises a model representing a tumor, the model comprising a combination of a plurality of homogeneous groups of cells, each of said homogeneous groups of cells representing a similarly behaving group of cells distributed between all the cell-cycle compartments.

9. The system of claim 8, wherein the system is adapted to calculate in each step, a number of cells in each sub-compartment of each compartment of each group according to factors including a previous state, parameters of tumor, tumor current microenvironment and drug concentration.

10. The system of claim 9 where spatial structure of the tumor is included in the model.

11. The system of claim 10, wherein the system is adapted to incorporate pharmacokinetics and pharmacodynamics, cytostatic effects, cytotoxic effects, and other effects of anticancer drugs on cell disintegration.

12. The system of claim 11 wherein the system is adapted to incorporate a dose-limiting toxicity into the model.

13. The system of claim 1, wherein said parameters specific to the individual comprise parameters related to tumor dynamics.

14. The system of claim 13, wherein said parameters related to tumor dynamics comprise age, weight, gender, percentage of limiting healthy cells, desired length of treatment protocol, previous reaction to treatment, molecular markers, genetic markers, pathologic markers and cytologic specifics.

15. A computer-implemented method for recommending an optimal treatment protocol for treating cancer using drugs for an individual, said method comprising:

creating a cancer system model;

enumerating a plurality of treatment protocols for treating cancer using drugs;

modifying the cancer system model based on parameters specific to the individual;

selecting an optimal treatment protocol from said plurality of treatment protocols based on the modified system model; and

recommending said optimal treatment.

16. The method of claim 15 wherein the cancer system model further comprises:

a process model of cancer development; and

a treatment model that models the effects of treating cancer with drugs.

17. The method of claim 16 wherein said process model incorporates a distribution of cycling cells and quiescent cells.

18. The method of claim 16 where a tumor cell cycle is divided into at least four compartments G1, S, G2 and M and a quiescent stage denoted by G0, wherein each of said four compartments is further subdivided into sub-compartments and an ith sub-compartment representing cells of age i in the corresponding compartment, wherein cells entering a compartment always enter a first sub-compartment of the compartment.

19. The method of claim 18 wherein the model traces development of cancer cells using a predetermined set of parameters by calculating a number of cells in each sub-compartment using stepwise equations.

20. The method of claim 19 wherein a probability vector is used to determine a fraction of cells that leaves any sub-compartment in a compartment to move to a first sub-compartment of the next compartment.

21. The method of claim 19 where a set of control functions uniquely determines an outcome of every single step, wherein said control functions comprise age of cells, state of a current population and associated environment.

22. The method of claim 19 wherein a tumor is modeled as a combination of a plurality of homogeneous groups of cells, each of said homogeneous groups of cells representing a similarly behaving group of cells distributed between all the cell-cycle compartments.

23. The method of claim 22, wherein in each step, a number of cells in each sub-compartment of each compartment of each group is calculated according to factors including a previous state, parameters of tumor, current tumor microenvironment and drug concentration.

24. The method of claim 23 where spatial structure of the tumor is included in the model.

25. The method of claim 24, wherein pharmacokinetics, pharmacodynamics, cytotoxic effects, cytostatic effects and other effects of anticancer drugs on cell disintegration are incorporated into the model.

26. The method of claim 25, wherein a dose-limiting toxicity is incorporated into the model.

27. The method of claim 15, wherein, said parameters specific to the individual comprise parameters related to tumor dynamics.

28. The method of claim 27, wherein said parameters related to tumor dynamics comprise age, weight, gender, percentage of limiting healthy cells, desired length of treatment protocol, previous reaction to treatment, molecular markers, genetic markers, pathologic markers and cytologic specifics.